TACE with adebrelimab and bevacizumab

Phase 2Monoclonal antibody

TThe First Affiliated Hospital of Xiamen University

TACE with adebrelimab and bevacizumab is one of 28 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Viread

Gilead

Preclinical

1 2

Sovaldi

Gilead

Preclinical

1 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Hepsera

Coreg

2 6

Vermox

WWim Janssens

Preclinical

1 7

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Opdivo

Bristol-Myers Squibb

Preclinical

2 10

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Hepatocellular Carcinoma

NCT05970666

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT05970666·71 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TACE with adebrelimab and bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TACE with adebrelimab and bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TACE with adebrelimab and bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Xiamen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: TThe First Affiliated Hospital of Xiamen University

TACE with adebrelimab and bevacizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News